瑞拉莫林治疗糖尿病胃轻瘫症状的疗效与安全性:一项随机安慰剂对照研究
这项2B期随机安慰剂对照研究纳入393例中重度糖尿病胃轻瘫症状患者,比较瑞拉莫林10 μg、30 μg、100 μg每日两次与安慰剂的疗效。12周时三个剂量组核心症状及复合评分均较安慰剂显著改善,胃排空加速,总体安全耐受良好。
要点
- 瑞拉莫林三个剂量组12周内糖尿病胃轻瘫复合及单项症状评分均较安慰剂显著降低(均P < .05)。
- 瑞拉莫林10 μg和30 μg组胃排空较安慰剂显著加速12%(P < .05),100 μg组P = .051。
- 14.5%接受瑞拉莫林的患者出现剂量相关的血糖控制恶化,部分需调整降糖药剂量。
核心结论
- 在中重度糖尿病胃轻瘫症状患者的2B期随机试验中,瑞拉莫林较安慰剂显著减轻核心症状和总体复合评分、加速胃排空,且总体安全、耐受良好。
研究设计与样本
- 12周、2B期随机安慰剂对照研究,纳入393例糖尿病胃轻瘫患者(男性37.7%,1型糖尿病9.9%,中位年龄58.2岁[范围20-76],中位体重指数31.4 kg/m2[范围18.2-60.1],HbA1c 7.6%[范围5.2-11.0])。
- 所有参与者13C-螺旋藻胃排空呼气试验T1/2≥79分钟(89.8%相对正常第90百分位85.75分钟延迟),近期有呕吐,胃轻瘫主要症状指数-每日日记评分≥2.6。
- 经2周单盲安慰剂导入期后随机分为安慰剂组(n=104)或瑞拉莫林10 μg组(n=98)、30 μg组(n=109)、100 μg组(n=82),均每日两次,共12周。
- 采用纵向混合效应模型重复测量分析,以基线和基线×周交互值为协变量。
主要发现
- 瑞拉莫林组呕吐频率较基线降低75%,但与安慰剂组比较差异无统计学意义。
- 全部3个瑞拉莫林剂量组的糖尿病胃轻瘫4项症状(复合或单项)在12周研究期间均较安慰剂组显著减轻(均P < .05,基于12周纵向分析)。
- 瑞拉莫林较安慰剂显著加速胃排空(较基线加速12%,10 μg和30 μg组P < .05;100 μg组P = .051)。
- 14.5%接受瑞拉莫林的患者出现剂量相关的血糖控制恶化,部分需调整胰岛素或其他降糖药剂量。
关键数值与推荐
- 呕吐频率:瑞拉莫林组较基线降低75%,与安慰剂组比较未达统计学显著。
- 症状评分:三个瑞拉莫林剂量组均较安慰剂组显著降低(均P < .05)。
- 胃排空:10 μg和30 μg组较安慰剂加速12%(P < .05);100 μg组P = .051。
- 血糖控制恶化:14.5%接受瑞拉莫林的患者,呈剂量相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Gastroparesis is a complication of diabetes with few treatment options. Relamorelin (also referred to as RM-131) is a selective, prokinetic agonist of ghrelin. We aimed to evaluate the efficacy of relamorelin on symptoms and gastric emptying (GE) in a 12-week, phase 2B study of diabetic patients with moderate to severe gastroparesis symptoms (DG). METHODS: We performed a study of 393 patients with DG (37.7% male; 9.9% with type 1 diabetes; median age, 58.2 years [range 20-76]; median body mass index, 31.4 kg/m2 [range, 18.2-60.1]; HbA1c level, 7.6%, [range, 5.2-11.0]). All participants had 13C-spirulina GE breath test T1/2 values of 79 minutes or more (with 89.8% delayed relative to 90th %ile of normal, 85.75 minutes), recent vomiting, and gastroparesis cardinal symptom index-daily diary scores of 2.6 or more. Patients were randomly assigned to groups given placebo (n=104) or relamorelin (10 μg [n=98], 30 μg [n=109], or 100 μg [n=82] twice daily) for 12 weeks, following a 2-week, single-blind, placebo run-in period. Patient-reported outcomes were determined from DG Symptom Severity daily e-diaries, in which patients recorded vomiting frequency and symptom scores (nausea, abdominal pain, postprandial fullness, and bloating) on a 0-10 scale. Endpoints were change from baseline in vomiting frequency, composite DG Symptom Severity score, GE, and safety. We performed longitudinal, mixed-effects model analysis using repeated measures, with baseline and baseline-by-week interaction values as covariates. RESULTS: Patients given relamorelin had a 75% reduction in vomiting frequency compared with baseline, but this difference was not significant compared with the placebo group. All 4 symptoms of DG (composite or individual symptoms) were significantly reduced over the 12-week study period in all 3 relamorelin dose groups compared with the placebo group (all P < .05, based on longitudinal analysis over 12 weeks). Relamorelin significantly accelerated GE from baseline compared with placebo (by 12%, P < .05 for the 10 μg and 30 μg groups; P = .051 for the 100 μg group). Dose-related worsening of glycemic control was noted in 14.5% of patients who received relamorelin; some required insulin or other diabetes drug dosage adjustments. CONCLUSIONS: In a phase 2B randomized trial of patients with moderate to severe DG, relamorelin significantly reduced core symptoms of DG and overall composite score compared with placebo, accelerated GE, and was generally safe and well tolerated. ClinicalTrials.gov Identifier: NCT02357420.
引用
- Camilleri M, McCallum RW, Tack J, et al. Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology. 2017. PMID: 28760384. doi:10.1053/j.gastro.2017.07.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。